In particular, the antigen-adjuvant conjugation strategy holds promise to enhance responses at reduced doses in vaccines protecting against viral infections, such as influenza, where CD8+ T-cell responses are critical but inflammation limits the use of synthetic TLR agonists at efficacious doses. Here, CD8A is linked to viral infectious disease.